Rock Springs Capital Management LP boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,384,269 shares of the biopharmaceutical company’s stock after purchasing an additional 47,868 shares during […]
StockNews.com lowered shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a hold rating to a sell rating in a research report released on Wednesday morning. Other analysts also recently issued research reports about the company. Cantor Fitzgerald restated an overweight rating and set a $114.00 price objective on shares of Ultragenyx Pharmaceutical in a […]
StockNews.com cut shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) from a hold rating to a sell rating in a research note released on Wednesday. Other research analysts have also issued research reports about the company. Cantor Fitzgerald reissued an overweight rating and issued a $114.00 target price on shares of Ultragenyx Pharmaceutical in a […]
Candriam S.C.A. lessened its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 18.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,480 shares of the biopharmaceutical company’s stock after selling 11,155 shares during the period. Candriam S.C.A. owned approximately 0.07% of Ultragenyx Pharmaceutical […]